The Globe and Mail reports in its Thursday, Feb. 12, edition that ATB Capital Markets analyst Frederico Gomes continues to rank Organigram Global "outperform." The Globe's David Leeder writes in the Eye On Equities column that Mr. Gomes gave his share target a 25-cent trim to $3.25. Analysts on average target the shares at $3.41. Mr. Gomes says in a note: "Organigram reported Q1/FY26 results that were a miss on estimates –– largely on the impact of lower international sales stemming from higher flower volumes not meeting international specifications, and lower sales in B.C. due to an eight-week union strike –– while highlighting the company's strengthening position on a year-over-year basis (with revenues and margins up materially). Although the company reiterated previous guidance and the headwinds encountered in the quarter were largely temporary in nature (B.C. volumes are already seeing a strong bounce-back), we believe the continued delay of EU-GMP certification could shift the realization of material international sales growth toward H2/FY26e and into FY2027e. As such, we have conservatively lowered our near-term growth and margin ramp expectations while largely maintaining our longer-term expectations."